Polypharma marks World Cholesterol Day

Polypharma marks World Cholesterol Day

Hamburg, Germany: Specialist pharmaceutical consultant and supplier Polypharma Technologies & Sciences GmbH (Polypharma) has been marking international Cholesterol Day.

The substance cholesterol is involved in metabolic processes in the body, primarily in the metabolization of fat. The body covers its need for cholesterol by producing it in the liver and taking it from food. If excessive cholesterol circulates in the body, it accumulates in the vascular walls and facilitates the occurrence of arteriosclerosis as a result.

Three forms of cholesterol

Cholesterol appears in the body in three forms: …

Read the whole article here:

Polypharma celebrates 30th Anniversary

Polypharma celebrates 30th Anniversary

Single partner

Polypharma offers a unique blend of services and skills that make it possible for it to act as a single partner accompanying local companies all the way from selection of target product through to actual receipt of raw materials for production.

“Over the years we have developed more than 200 approved drug dossiers for our partners, meeting real local needs, along with tech transfer and up-scaling services to succeed with their own production,” noted Polypharma founder and general manager, Mohamed Ben M’Barek.

Facilitating local production

At the time Polypharma was born, a very high percentage of African and Middle Eastern medicines were imported from Europe and North America as well as Asia, with limited local production largely carried out by public institutions, typically producing generics under license. Almost total absence of laboratories also made it very challenging to check imported medicines for quality or efficacy.

Read the whole article here:

Sodium hyaluronate 0.3% Serum

Polypharma has developed a Sodium hyaluronate 0.3% serum. Sodium hyaluronate, as hyaluronic acid, is a natural component of the skin and is used to smooth and tighten the skin, as well as to moisturise it.

Polypharma’s 30th anniversary

Next April Polypharma will have its 30th anniversary.

Much has been achieved during this period: development of a comprehensive  portfolio of human medicines, expansion of the generic portfolio to include veterinary medicine, support for the construction of local production facilities.

If you are interested in learning more about our corporate history, please consult our Milestones.


The most important objective since the company was founded remains:

To encourage local production in order to reduce drug imports in the MENA, East and West Africa regions and to combat counterfeiting

Why Polypharma cannot recommend its partners to package purchased bulk medicines

Many new customers find it interesting to pack already manufactured goods as a first step before producing their own medicines. Here are the reasons why Polypharma is against it:

  • From a pharmaceutical point of view, production and packaging in a GMP-compliant production line is the highest priority for the quality of the pharmaceuticals
  • Only with self-produced goods can you be 100% sure of the quality of the finished product
  • If the manufacturing process and subsequent packaging is interrupted, GMP-compliant goods cannot be guaranteed.
  • If finished pharmaceuticals are not packaged immediately after production, there is always the risk that they will be affected by fluctuations in humidity and temperature.
  • Bulk pharmaceuticals can be damaged during transport, resulting in a high level of loss of goods.
  • If you want to register bulk goods under your own name, you need a complete dossier, as well as all documentation of the active ingredient for registration with the local authority. It is questionable whether all necessary documentation can be obtained from the bulk producer.

Therefore, we recommend directly to produce your own production. If you would like further advice on this, please feel free to contact us.

Technologies & Sciences GmbH

Grosse Reichenstrasse 27
20457 Hamburg
+49 (0)40 37 480 3-0